Latest news with #ENABLE
Yahoo
5 days ago
- Business
- Yahoo
British Business Bank names Julia Bond as nonexecutive director
The British Business Bank has appointed Julia Bond as nonexecutive board director and chair of its remuneration committee. Her appointment as board director was effective from 19 May, and she will assume the role of chair of the remuneration committee from 1 July, the bank said in its press statement. Bond has extensive experience in global finance, public service, and long-term investment. She currently holds nonexecutive positions at Impax Asset Management, International Public Partnerships, UK Strategic Command, and the Foreign, Commonwealth and Development Office. British Business Bank chair Stephen Welton said: 'Julia brings with her a great deal of capability and experience in both the private and public sector, and I am pleased to welcome her onto the board of the British Business Bank. 'She joins at a pivotal time for the bank, at which we are set to play an even bigger role in shaping the future of the UK economy as a major catalyst to drive growth and access to finance, whilst helping to crowd in greater institutional investment.' Bond was previously a senior executive at Credit Suisse, where she led global fixed-income businesses and managed relationships with sovereign wealth funds, central banks, and institutional investors across Europe, Asia, and the Americas. She has also served as a nonexecutive director for the National Health Service, European Assets Trust, and ACCA, where she chaired multiple board committees, including those focused on audit, remuneration, environmental, social, and governance, and risk. Commenting on the new role, Bond said: 'The British Business Bank occupies a practically unique position as a UK public sector organisation which operates in commercial finance markets, and I look forward to bringing my knowledge and expertise in each of those sectors to my new role. 'I am delighted to be joining the bank at an exciting time for the organisation, as it significantly expands the scope of its activities.' Recently, the British Business Bank reached £5bn ($4.08bn) in lending through its ENABLE structured guarantee programmes. These programmes, including ENABLE Guarantees and ENABLE Build, have delivered more than £3bn to businesses outside London and the South East of England, supporting small and medium-sized enterprises across the UK, the bank said. "British Business Bank names Julia Bond as nonexecutive director" was originally created and published by Leasing Life, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business News Wales
6 days ago
- Business
- Business News Wales
British Business Bank Reaches £5bn Lending Milestone for Structured Guarantee Programmes
The British Business Bank has reached the landmark milestone of £5 billion of lending across its structured guarantee programmes, ENABLE Guarantees and ENABLE Build. More than £3 billion has been delivered to businesses outside London and the South East. A total of £155.95 million has been provided in Wales. The ENABLE Guarantees programme is designed to encourage additional lending to smaller and medium-sized businesses. Participating institutions are incentivised by a government-backed guarantee to support defined portfolios of debt finance in return for a fee. Smaller and medium-sized businesses across the UK have benefited significantly from the programme, British Business Bank said. The structured guarantee programmes have provided more than £2.3 billion of support to the construction and housing sectors, including around £1.2 billion under ENABLE Build. Other notable sectors benefiting include hospitality, with more than £270 million, and agriculture, with more than £260 million. Since the first transaction in 2017, these structured guarantee programmes have supported both bank and non-bank financial institutions to unlock more lending to smaller and medium-sized businesses. The ENABLE Guarantees programme is open to all UK banks, UK branches of foreign banks, asset and asset-based finance providers as well as certain other categories of lenders which lend, or intend to lend, to viable small and medium-sized enterprises operating in the UK. The ENABLE Build programme operates in a similar manner to the ENABLE Guarantees programme, but is focused on encouraging additional lending to smaller and medium-sized housebuilders in the UK. Michael Strevens, Managing Director, Structured Financial Institutions, British Business Bank, said: 'It's incredibly rewarding to reflect on the volume of lending to smaller and medium-sized businesses and the number of homes built that we've helped enable over the years. Our focus has always been on evolving our support to strengthen UK businesses, and it's encouraging to see those efforts bearing fruit. Looking ahead, we're focused on being more proactive — working closely with lenders to understand their challenges and tailor solutions that fit. That's how we'll unlock the next £5 billion — and do so with greater pace and purpose.' Adam Bovingdon, Head of Property Development, United Trust Bank (UTB), said: 'UTB helped the British Business Bank develop its ENABLE Guarantees programme to be suitable for supporting housebuilding and was the first lender to take advantage of it when it was made available to the sector in 2017. We subsequently signed up to ENABLE Build and I am delighted to say that earlier this year UTB surpassed £1 billion of ENABLE guaranteed lending across both schemes, delivering nearly 450 loan facilities to SME housebuilders and supporting the creation of around 4,700 new homes. Bearing in mind that during this period lenders and housebuilders have also had to contend with the Covid-19 pandemic and considerable economic and political volatility, it's clear just how important this support has been. ENABLE is an excellent example of successful state and private sector cooperation.' Ravi Anand, Managing Director of ThinCats, said: 'The British Business Bank's ENABLE Guarantees programme has been a huge contribution to the £1 billion of funding we have undertaken post COVID. The scheme 'does what it says on the tin'— enabling senior bank appetite to allow ThinCats to fund growth initiatives of UK mid-sized SMEs and in turn enabling a positive contribution to UK GDP.' Brian Berry, Chief Executive of the Federation of Master Builders (FMB), said: 'It's positive to see that small housebuilders have taken advantage of ENABLE schemes. Financing is one of the top issues holding back small developers from building new homes and the more finance options there are the better. The ENABLE Build scheme helps aid diversification of the UK's housing market, which is essential to deliver the Government's ambition of 1.5 million new homes.'
Yahoo
6 days ago
- Business
- Yahoo
British Business Bank hits £5bn in structured guarantee programmes
The British Business Bank has reached £5bn in lending through its ENABLE structured guarantee programmes. These programmes, including ENABLE Guarantees and ENABLE Build, have delivered more than £3bn to businesses outside London and the South East, supporting smaller and medium-sized enterprises (SMEs) across the UK, the bank said. A total of £500m has been allocated to each of the North West, East Midlands and East of England regions. The ENABLE Guarantees programme is designed to encourage additional lending to SMEs by providing a government-backed guarantee to participating institutions, which support defined portfolios of debt finance in return for a fee. The structured guarantee programmes provided more than £2.3bn of support to the construction and housing sectors, including approximately £1.2bn under ENABLE Build. Other sectors such as hospitality and agriculture have also benefitted, receiving more than £270m and £260m, respectively. Since the first transaction in 2017, these programmes have enabled both bank and non-bank financial institutions to increase lending to SMEs. The ENABLE Guarantees programme is open to all UK banks, UK branches of foreign banks, asset and asset-based finance providers, and certain other lenders that lend to viable SMEs in the UK. The ENABLE Build programme operates similarly to ENABLE Guarantees but focuses on encouraging additional lending to smaller and medium-sized housebuilders in the UK. British Business Bank Structured Financial Institutions managing director Michael Strevens said: 'It is incredibly rewarding to reflect on the volume of lending to smaller and medium-sized businesses and the number of homes built that we have helped enable over the years. 'Our focus has always been on evolving our support to strengthen UK businesses, and it is encouraging to see those efforts bearing fruit. Looking ahead, we are focused on being more proactive – working closely with lenders to understand their challenges and tailor solutions that fit. That is how we will unlock the next £5bn – and do so with greater pace and purpose.' "British Business Bank hits £5bn in structured guarantee programmes" was originally created and published by Leasing Life, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
08-04-2025
- Business
- Yahoo
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We were pleased to share three presentations yesterday which we believe demonstrate our continued commitment to improving the patient experience and understanding the long term and real-world profile of BRIUMVI.' Mr. Weiss continued, 'The results of the retrospective ENAMOR survey, which includes data from approximately 400 individuals across 21 MS centers who have been treated with BRIUMVI in the real-world setting, showed a favorable tolerability profile, including a lower rate of infusion related reactions at the first BRIUMVI dose than was observed in the ULTIMATE Phase 3 trials. Interestingly, approximately 90% of surveyed patients were given acetaminophen as a pre-medication in this real-world setting, whereas it was excluded as a premed as per protocol in the ULTIMATE Phase 3 trials potentially offering a rationale for the lower rate of infusion related reactions observed. We plan to further evaluate the efficacy and tolerability of BRIUMVI in the real world setting through the ENABLE Phase 4 96-week observational study which will enroll approximately 500 patients across approximately 100 MS centers in the United States. Lastly, we were encouraged to see in the presentation by Dr. Steinman, that after five years of BRIUMVI treatment, the frequency of serious infections remained consistent with the ULTIMATE Phase 3 trials and there were no observed cases of PML.' TG PRESENTATIONS:Poster Title: Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) Lead Author: Dr. Ed Fox – TG Therapeutics - National Physician Liaison – VP, MS Global Operations Poster Title: ENABLE: The First Phase 4 Observational Study for Patients with Relapsing MS Treated with Ublituximab in Real World Clinical Setting Lead Author: Dr. Ed Fox – TG Therapeutics - National Physician Liaison – VP, MS Global Operations Poster Title: No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) and Serious Infections (SI) with Long-term Ublituximab (UBL) Treatment in Patients with Relapsing Multiple Sclerosis (RMS) Lead Author: Lawrence Steinman, MD, Standford University, Standford, CA The above presentations are also available on the Publications page, located within the Pipeline section, of the Company's website at ABOUT THE ULTIMATE I & II PHASE 3 TRIALSULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or teriflunomide, the active comparator, given orally as a 14 mg daily dose with IV placebo administered on the same schedule as BRIUMVI. Both studies enrolled patients who had experienced at least one relapse in the previous year, two relapses in the previous two years, or had the presence of a T1 gadolinium (Gd)-enhancing lesion in the previous year. Patients were also required to have an Expanded Disability Status Scale (EDSS) score from 0 to 5.5 at baseline. The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries. These trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University. Additional information on these clinical trials can be found at (NCT03277261; NCT03277248). ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IVBRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses. BRIUMVI is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease. A list of authorized specialty distributors can be found at IMPORTANT SAFETY INFORMATIONContraindications: BRIUMVI is contraindicated in patients with: Active Hepatitis B Virus infection A history of life-threatening infusion reaction to BRIUMVI WARNINGS AND PRECAUTIONS Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization. Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment. Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI- treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved. Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI. HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HB surface antigen (HBsAg) and anti-HB tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment. Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies. If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis. If PML is confirmed, treatment with BRIUMVI should be discontinued. Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted. Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is recommended in females of reproductive potential prior to each infusion. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose. Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections. Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit ABOUT BRIUMVI PATIENT SUPPORTBRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at ABOUT MULTIPLE SCLEROSISRelapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing- remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately 85% are initially diagnosed with RRMS.1,2 The majority of people who are diagnosed with RRMS will eventually transition to SPMS, in which they experience steadily worsening disability over time. Worldwide, more than 2.3 million people have a diagnosis of MS.1 ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. Cautionary StatementThis press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below. Such forward looking statements include but are not limited to statements regarding the results of the ULTIMATE I & II Phase 3 studies, the ENHANCE Phase 3b study, and BRIUMVI as a treatment for relapsing forms of multiple sclerosis (RMS). Additional factors that could cause our actual results to differ materially include the following: the risk that the data from the ULTIMATE I & II or ENHANCE trials that we announce or publish may change, or the product profile of BRIUMVI may be impacted, as more data or additional endpoints are analyzed; the risk that data may emerge from future clinical studies or from adverse event reporting that may affect the safety and tolerability profile and commercial potential of BRIUMVI; the risk that any individual patient's clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials such as ULTIMATE I and II; the risk that BRIUMVI will not be commercially successful; our ability to expand our commercial infrastructure, and successfully market and sell BRIUMVI in RMS; the Company's reliance on third parties for manufacturing, distribution and supply, and a range of other support functions for our commercial and clinical products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements; the uncertainties inherent in research and development; and general political, economic and business conditions, including the risk that the ongoing COVID-19 pandemic could have on the safety profile of BRIUMVI and any of our other drug candidates as well as any government control measures associated with COVID-19 that could have an adverse impact on our research and development plans or commercialization efforts. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. CONTACT: Investor RelationsEmail: ir@ (8489), Option 4 Media Relations:Email: media@ (8489), Option 6 1. MS Prevalence. National Multiple Sclerosis Society website: Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Datamonitor in to access your portfolio
Associated Press
14-02-2025
- Business
- Associated Press
Enlitic, Inc. to Showcase AI Enabled Workflows at ViVE 2025
Highlights Location: Nashville Music City Center, Nashville, TN Enlitic Booth: 2308 FORT COLLINS, Colo., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Enlitic, Inc. will demonstrate its latest version of data standardization software, Ensight™ 2.0 offering: Standardized study and series descriptions generation Protected Health Information (PHI) deidentification Enhanced radiologist reporting workflows Improved data quality New revenue opportunities for healthcare providers Michael Sistenich, CEO of Enlitic, stated, 'We are excited to present our cutting-edge ai enabled workflow and data migration solutions at ViVE 2025. Our participation underscores our commitment to addressing the long-standing challenges in healthcare data utilization and contributing to better outcomes for our customers.' A highlight of Enlitic's presence at ViVE 2025 will be ENABLE, Enlitic's newest offering innovative search and cohort development modules. These new additions to Enlitic's product lineup promise to further revolutionize the field of radiology AI. The recent acquisition of Laitek has enabled the two companies to combine forces and deliver AI enabled data migration that promises to greatly reduce the time required to migrate DICOM studies while vastly improving the data quality. Combined with Enlitic's ENDEX data standardization, data migration takes on a whole new perspective as data quality becomes a key differentiator. About Enlitic At Enlitic, we empower healthcare systems to enhance the quality of their medical imaging data using the capabilities of artificial intelligence. Enlitic has developed an intelligent data framework that powers radiology workflows, orchestrates data between systems, and enables greater comprehension of what information resides in archives thereby unlocking new revenue opportunities, generating cost-savings, and improving healthcare delivery. Enlitic enables providers to realize value from decades of stored data. Contact: Enlitic Media Relations David Wilson
